Formulation
AssigneeIndex Pharmaceuticals AB
InventorsPaul Alhadeff, Christine Dieterich Johansson, Peter Zerhouni, Wei Tian, Graeme William Andrew Hamilton Johnston
Life of this patent
Estimating the term…
Abstract
The present invention relates a formulation and capsule suitable for oral administration. The invention further relates to the use of the formulation and capsule for treating inflammatory bowel diseases, for instance ulcerative colitis (UC) or Crohn's disease.
Claims24
A formulation suitable for oral administration comprising (i) an oligonucleotide containing a CpG dinucleotide and having 19 to 40 nucleotides, wherein the oligonucleotide comprises the sequence 5′-GGAACAGTTCGTCCATGGC-3′ (SEQ ID NO:2), and (ii) esters which are monoesters and/or diesters of propylene glycol with caprylic acid or monoesters and/or diesters of glycerol with caprylic acid.
A capsule suitable for oral administration, said capsule comprising:
- a) a gelatin container, and within the container b) a formulation comprising (i) an oligonucleotide containing a CpG dinucleotide and having 19 to 40 nucleotides, wherein the oligonucleotide comprises the sequence 5′-GGAACAGTTCGTCCATGGC-3′ (SEQ ID NO:2), and (ii) esters which are monoesters and/or diesters of propylene glycol with caprylic acid or monoesters and/or diesters of glycerol with caprylic acid.
A method of treating inflammatory bowel disease in a subject, the method comprising orally administering to said subject a) a formulation comprising an oligonucleotide containing (i) a CpG dinucleotide and having 19 to 40 nucleotides, wherein the oligonucleotide comprises the sequence 5′-GGAACAGTTCGTCCATGGC-3′ (SEQ ID NO:2);
- and (ii) esters which are monoesters and/or diesters of propylene glycol with caprylic acid or monoesters and/or diesters of glycerol with caprylic acid;
- or
- b) a capsule comprising:
- i) a gelatin container, and within the container
- ii) a formulation comprising an oligonucleotide containing a CpG dinucleotide and having 19 to 40 nucleotides, wherein the oligonucleotide comprises the sequence 5′-GGAACAGTTCGTCCATGGC-3′ (SEQ ID NO:2);
- and esters which are monoesters and/or diesters of propylene glycol with caprylic acid or monoesters and/or diesters of glycerol with caprylic acid.
Dependencies are inferred from the claim text.